Content about Combivir

May 26, 2011

Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.

JERUSALEM — Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.

Teva said it will launch generic Combivir tablets (lamivudine and zidovudine) and is eligible for a 180-day period of marketing exclusivity, according to the Food and Drug Administration. The drug maker is expected to ship the drug in fourth quarter 2011, per terms of a settlement agreement between Teva, Glaxo Group and ViiV Healthcare.

January 20, 2011

The Food and Drug Administration has given tentative approval to an antiretroviral treatment for children with HIV and AIDS under the President’s Emergency Plan for AIDS Relief program.

PITTSBURGH — The Food and Drug Administration has given tentative approval to an antiretroviral treatment for children with HIV and AIDS under the President’s Emergency Plan for AIDS Relief program.

Mylan announced Thursday that its subsidiary, Matrix Labs, had received the tentative approval for lamivudine and zidovudine tablets in the 30-mg/60-mg strength. The drug is a generic version of Combivir, made by ViiV Healthcare, a company specializing in HIV and AIDS created as a partnership between Pfizer and GlaxoSmithKline.